Alcura Obtains Manufacturing and Importation Authorization License, Expanding its Capabilities to Support Cell & Gene Therapy Developers
Alcura, a provider of specialized clinical trial services and a part of Cencora, has been granted a Manufacturing and Importation Authorization (MIA) license for cell and gene therapies (CGT) by the Spanish Agency of Medicines and Medical Devices. The certification, coupled with Alcura’s cryogenic storage capacity and team of experts, enables the company to provide enhanced support to developers planning to bring investigational or commercially approved CGTs into Europe.
Alcura can now import CGTs — or advanced therapy medicinal products (ATMPs) — manufactured outside the European Union (EU) via its facility in Viladecans, Spain. The batches are stored in temperature-controlled units while Alcura’s team of qualified persons conduct necessary reviews, including ensuring batches are manufactured in compliance with the clinical trial or marketing authorization and Good Manufacturing Practice (GMP) requirements. Once the batch is certified, Alcura will release the products for distribution across Europe.
“Managing ATMPs requires a deep understanding of the intricate regulatory requirements and specialized logistical support to ensure product quality and safety,” said Javier Casas,Vice President and Regional Director at Alliance Healthcare and Vice President of Clinical Trials. “We continue to expand our portfolio of solutions through strategic investments in infrastructure and innovative services, allowing us to offer more comprehensive support that can be tailored to our partners’ needs. With this MIA license, we can import and release ATMPs developed outside the EU, helping to facilitate efficient and secure access to quality products across Europe.”
There are nearly 2,000 clinical trials underway globally, according to the Alliance for Regenerative Medicine. In its 2024 State of the Industry Briefing, ARM forecasted a possible 17 CGT regulatory approvals across the United States and Europe this year.
Alcura offers a variety of logistics and regulatory services, including importation, batch certification, storage, packaging and labeling, export, and regulatory assessment. Alcura recently added liquid nitrogen tanks and additional temperature-controlled capabilities at its Viladecans facility, expanding its capacity to hold products that require storage at frozen or cryogenic (as low as -196 degrees Celsius) temperatures.
The new capabilities further expand the services available to CGT developers via Cencora’s network of businesses, including third-party logistics services, regulatory consulting, market access and reimbursement support, clinical trial and commercial distribution and patient services.
“The growing pipeline of cell and gene therapies offers tremendous promise for patients worldwide,” said Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at Cencora. “Alcura’s MIA certification reflects the commitment across Cencora to continually elevate and expand our capabilities, enabling us to deliver integrated support across the product lifecycle to help our partners advance innovation and ensure they can reach the patients who need them.”
As part of its commitment to support CGT, Alcura is hosting a summit on September 19, 2024, “Overcoming Hurdles to Promote Advancements in Cell and Gene Therapies,” which will convene leaders across the industry to discuss the latest developments in the CGT sector and strategies to support the unique logistics and distribution requirements. For more information on Alcura’s capabilities or to register for the event, visit Alcura’s website.
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at www.cencora.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240814175480/en/
Contacts
Mike Iorfino
610.545.9189
mike.iorfino@cencora.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 10:00:00 EEST | Press release
Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C
IEEE Standards Commitment to Advancing AI Governance Includes Impactful Contributions to New International AI Standards Exchange11.7.2025 09:00:00 EEST | Press release
IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and its IEEE Standards Association (IEEE SA) announced today that its portfolio of over 100 global AI-related standards is included in the new International AI Standards Exchange. This Exchange is a centralized repository of international AI standards with the aim to foster collaboration and responsible AI development worldwide. IEEE and its AI global standards were recognized in the 2024 United Nations AI Advisory Body’s Report, Governing AI for Humanity, which created the impetus for the AI Standards Exchange. Due to its impactful AI standards and related work, IEEE, a major standards body, was included as a partner in the establishment of the Exchange. IEEE President and CEO Kathleen Kramer, who is speaking at the AI for Good Summit this year at the High-Level AI Standards Panel,shares, “IEEE’s mission of advancing technology for the benefit of humanity is foundational to ou
The Global AI Defense Challenge 2025 Launched to Fight Bad AI with Good AI11.7.2025 05:29:00 EEST | Press release
The Global AI Defense Challenge 2025, co-hosted by the China Society of Image and Graphics, the Cloud Security Alliance Greater China Region, and Ant Group, was launched on July 10, as part of the AI Innovation Competitions at the 2025 INCLUSION·Conference on the Bund. With the rapid development of large models, AI technologies and applications are increasingly integrated into sectors such as financial services, healthcare, and user interactions with various gadgets and terminals. This evolution raises heightened risk of deepfake-related identity attacks, becoming a growing concern for security technology experts. To address this global challenge and support the sustainable and reliable development of the AI industry, the Global AI Defense Challenge was hosted to facilitate collaboration between the academic and industry communities. In 2024, the competition attracted over 3,200 participants from more than 2,700 teams across 18 countries and regions worldwide. This year's competition f
DNP to Open First Overseas R&D Center in the Netherlands11.7.2025 04:00:00 EEST | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) will open its first overseas Research and Development (R&D) Center in the Netherlands in September 2025. The new R&D Center will be located at the High Tech Campus Eindhoven (HTCE), and aims to promote global R&D, as well as accelerate innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250704911943/en/ Aerial view of HTCE (Copyright: High Tech Campus Eindhoven) HTCE is one of the leading innovation hubs in Europe, where approximately 300 companies and research institutes, and more than 12,500 researchers, engineers and entrepreneurs come together to develop innovative technologies and products. As an initial project, DNP will promote R&D into Co-Packaged Optics, which integrates optical communication technology with electronic technology to achieve a high information processing performance. Co-Packaged Optics is attracting attention as a next-generation semiconductor t
Parse-Enabled Study Maps Neuronal Pathways with Potential Implications for Neurodegenerative Disease Research10.7.2025 23:18:00 EEST | Press release
Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced a groundbreaking study published in the journal Science that utilized Parse’s single cell technology to uncover how signaling pathways drive the formation of diverse neuron cell subtypes. By linking specific signals to cell fate outcomes, this research provides a powerful framework for generating defined cell types in vitro, which has broad relevance to human biology, disease, and therapeutic development. Principle investigators Dr. Barbara Treutlein, Head of the Quantitative Development Biology Lab at ETH Zurich, and Dr. Gray Camp, Group Leader at the Institute of Human Biology at Roche, led the experiment. Through an elegantly designed screening approach spanning 480 morphogens across 700,000 cells, the research team was able to explore how different morphogens interact with pro-neural transcription factors, thereby generating pure populations of different types of neu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom